Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia
Abstract
BACKGROUND: The differentiation of Alzheimer's disease (AD) from vascular dementia (VaD) is hampered by clinical diagnostic criteria with disappointing sensitivity and specificity. The objective of this study was to investigate whether cerebrospinal fluid (CSF) levels of total tau protein (t-tau), amyloid beta42 protein (Abeta42), and tau phosphorylated at threonine 181 (p-tau181) are useful biomarkers to distinguish AD patients from VaD patients. METHODS: We measured CSF levels of p-tau181, Abeta42, and t-tau in 86 patients with a clinical diagnosis of AD or VaD and in 30 control participants. RESULTS: Optimal differentiation between AD and VaD was achieved by using the ratio of the CSF levels of Abeta42 and p-tau181 (Q Abeta42/p-tau) with sensitivity, specificity, positive and negative predictive values all > or = 85%. CONCLUSIONS: Our results support further efforts to prospectively validate the use of Q Abeta42/p-tau as a biomarker to discriminate between AD and VaD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The CSF tau/Aβ ratio is a powerful predictor of cognitive decline and can distinguish vascular dementia from Alzheimer's disease.
“We hypothesized that CLU levels were also associated with CSF tau/Aβ ratio, a powerful predictor of cognitive decline that can be used to discriminate between vascular dementia and AD (de Jong, et al., 2006,Fagan, et al., 2007,Harari, et al., 2014)”
From A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin (2016) · cites this paper as de Jong, et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921 · see citing works
Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics
de la Torre, J. C. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00683-0 · Cited by 834 · see citing works
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 702 · see citing works
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664 · see citing works
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450 · see citing works
Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436 · see citing works
Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · see citing works
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357 · see citing works
Büerger, K., Zinkowski, R. P., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann‐Kiefer, K., DeBernardis, J. F., Kerkman, D. J., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1267 · Cited by 275 · see citing works
Itoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · see citing works
Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias
López, O. L., Litvan, I., Catt, K. E., Stowe, R., Klunk, W. E., Kaufer, D., Becker, J. T., & DeKosky, S. T. (1999) · Neurology · doi:10.1212/wnl.53.6.1292 · Cited by 238 · see citing works
Clinicopathological Validation Study of Four Sets of Clinical Criteria for Vascular Dementia
Gold, G., Bouras, C., Canuto, A., Bergallo, M. F., Herrmann, F. R., Hof, P. R., Mayor, P.-A., Michel, J.-P., & Giannakopoulos, P. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.82 · Cited by 217 · see citing works
Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204 · see citing works
Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases
Verbeek, M., de Jong, D., & Kremer, H. (2003) · Annals of Clinical Biochemistry · doi:10.1258/000456303321016141 · Cited by 116 · see citing works
Self-citationSchönknecht, P., Pantel, J., Hunt, A. M., Volkmann, M., Buerger, K., Hampel, H., & Schröder, J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01481-7 · Cited by 68 · see citing works
Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.
Leszek, J., Małyszczak, K., Janicka, B., Kiejna, A., & Wiak, A. (2003) · PubMed · Cited by 25 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS- ADRDA Work Group. Neurology. 1984;34:939-944.
Cited by
Sorted by citations
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
Hampel, H. J., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 532 · see citing works
Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia
Skillbäck, T. B., Farahmand, B. Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A. B., Winblad, B. G., Schott, J. M., et al. (2015) · Brain · doi:10.1093/brain/awv181 · Cited by 215 · see citing works
Cognitive and Behavioral Neurology
Finger, E. C., & Daffner, K. R. (2011) · Springer eBooks · doi:10.1007/978-0-387-88555-1_8 · Cited by 200 · see citing works
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.086 · Cited by 164 · see citing works
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152 · see citing works
Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 144 · see citing works
Yang, C., Chiu, M., Chen, T., Chang, H.-L., Liu, B.-H., & Yang, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170810 · Cited by 143 · see citing works
CSF neurofilament proteins in the differential diagnosis of dementia
de Jong, D., Jansen, R. W. M. M., Pijnenburg, Y. A. L., van Geel, W. J. A., Borm, G. F., Kremer, H. P. H., & Verbeek, M. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107326 · Cited by 120 · see citing works
Self-citationAlzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 109 · see citing works
Brooks, L., & Loewenstein, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt52 · Cited by 102 · see citing works
D’Onofrio, G., Sancarlo, D., Panza, F., Copetti, M., Cascavilla, L., Paris, F., Seripa, D., Matera, M. G., Solfrizzi, V., Pellegrini, F., et al. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322582 · Cited by 99 · see citing works
Aluise, C. D., Robinson, R. A. S., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 92 · see citing works
Cerebrospinal Fluid α-Synuclein Does Not Discriminate Between Dementia Disorders
Spies, P. E., Melis, R. J. F., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0955 · Cited by 93 · see citing works
Self-citationPetrushina, I., Ghochikyan, A., Mktrichyan, M., Mamikonyan, G., Movsesyan, N., Davtyan, H., Patel, A. J., Head, E., Cribbs, D. H., & Agadjanyan, M. G. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3201-07.2007 · Cited by 92 · see citing works
Xu, W., Tan, L., Su, B., Yu, H., Bi, Y., Yue, X., Dong, Q., & Yu, J. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12117 · Cited by 91 · see citing works
Current state and future directions of neurochemical biomarkers for Alzheimer's disease
de Jong, D., Kremer, B. P. H., Rikkert, M. G. M. O., & Verbeek, M. M. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.320 · Cited by 82 · see citing works
Self-citationA potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin
Deming, Y., Xia, J., Cai, Y., Lord, J., Holmans, P., Bertelsen, S., Holtzman, D., Morris, J. C., Bales, K., Pickering, E. H., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.009 · Cited by 66 · see citing works
Xu, W., Initiative, A. D. N., Zhang, C. M., Li, J., Tan, C., Cao, X., Tan, L., & Yu, J. (2019) · Aging · doi:10.18632/aging.101971 · Cited by 74 · see citing works
Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease
Tuwaig, M., Savard, M., Jutras, B., Poirier, J., Collins, D. L., Rosa‐Neto, P., Fontaine, D. J., & Breitner, J. C. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170545 · Cited by 69 · see citing works
Biological fluid biomarkers in neurodegenerative parkinsonism
Eller, M., & Williams, D. R. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.135 · Cited by 71 · see citing works
Li, S., Lin, C.-W., Wei, K., Huang, C.-Y., Hsu, P., Liu, H.-L., Lin, Y.-J., Lin, S.-C., Yang, H., & Ma, C.-C. M. (2016) · Scientific Reports · doi:10.1038/srep25155 · Cited by 70 · see citing works
Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β42 and Tau Proteins
Reijn, T. S., Rikkert, M. G. M. O., van Geel, W. J. A., de Jong, D., & Verbeek, M. M. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081679 · Cited by 66 · see citing works
Self-citationOuwens, D. M., van Duinkerken, E., Schoonenboom, S. N. M., de Wiza, D. H., Klein, M., van Golen, L. W., Pouwels, P. J. W., Barkhof, F., Moll, A. C., Snoek, F. J., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3333-6 · Cited by 62 · see citing works
Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 61 · see citing works
A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
Lehmann, S., Dumurgier, J., Schraen‐Maschke, S., Wallon, D., Blanc, F., Magnin, É., Bombois, S., Bousiges, O., Campion, D., Cretin, B., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt267 · Cited by 55 · see citing works
Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis
Struyfs, H., Niemantsverdriet, E., Goossens, J., Fransén, E., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00138 · Cited by 52 · see citing works
Ray, L., Khemka, V. K., Behera, P., Bandyopadhyay, K., Pal, S., Pal, K., Basu, D., & Chakrabarti, S. (2013) · Europe PMC (PubMed Central) · Cited by 51 · see citing works
Biological markers for early detection and pharmacological treatment of Alzheimer's disease
Hampel, H. J., Broich, K., Hoessler, Y. C., & Pantel, J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/hhampel · Cited by 50 · see citing works
Deming, Y. K., Li, Z., Benítez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 48 · see citing works
Slats, D., Claassen, J. A. H. R., Spies, P. E., Borm, G. F., Besse, K., van Aalst, W., Tseng, J., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.07.008 · Cited by 48 · see citing works
Self-citationFerreira, D., Rivero‐Santana, A., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00287 · Cited by 46 · see citing works
Neurochemical biomarkers in the differential diagnosis of movement disorders
Mollenhauer, B., & Trenkwalder, C. (2009) · Movement Disorders · doi:10.1002/mds.22510 · Cited by 45 · see citing works
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic
Kester, M. I., Boelaarts, L., Bouwman, F. H., Vogels, R. L. C., Groot, E. R., van Elk, E. J., Blankenstein, M. A., van der Flier, W. M., & Scheltens, P. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000313534 · Cited by 41 · see citing works
Kokkinou, M., Beishon, L., Smailagic, N., Noel-Storr, A. H., Hyde, C., Ukoumunne, O. C., Worrall, R., Hayen, A., Desai, M., Ashok, A. H., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010945.pub2 · Cited by 42 · see citing works
Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model
Yang, S., Kim, J., Lee, M. J., & Kim, Y. S. (2015) · Scientific Reports · doi:10.1038/srep15703 · Cited by 40 · see citing works
Santangelo, R., Cecchetti, G., Bernasconi, M. P., Cardamone, R., Barbieri, A., Pinto, P., Passerini, G., Scomazzoni, F., Comı, G., & Magnani, G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170186 · Cited by 40 · see citing works
CSF biomarkers in neurodegenerative and vascular dementias
Llorens, F., Schmitz, M., Ferrer, I., & Zerr, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.003 · Cited by 39 · see citing works
CSF Tau, Aβ42, and MHPG Differentiate Dementia with Lewy Bodies from Alzheimer's Disease
Aerts, M., Esselink, R., Claassen, J. A., Abdo, W. F., Bloem, B., & Verbeek, M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110482 · Cited by 37 · see citing works
Self-citationTang, W., Huang, Q., Wang, Y., Wang, Z.-Y., & Yao, Y.-Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.015 · Cited by 38 · see citing works
Orellana, C., Ferreira, D., Muehlboeck, J., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Soininen, H. S., Lovestone, S., Simmons, A., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000442443 · Cited by 36 · see citing works
Xu, W., Wei, F., Shen, X., Bi, Y., Ma, Y., Li, J., Dong, Q., Tan, L., & Yu, J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.07.004 · Cited by 35 · see citing works
Neuroimmune Biomarkers in Mental Illness
Herron, J. W., Nerurkar, L., & Cavanagh, J. (2018) · Current topics in behavioral neurosciences · doi:10.1007/7854_2018_45 · Cited by 34 · see citing works
Movsesyan, N., Mkrtichyan, M., Petrushina, I., Ross, T. M., Cribbs, D. H., Agadjanyan, M. G., & Ghochikyan, A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.08.016 · Cited by 33 · see citing works
Tang, W. X., Huang, Q., Yao, Y., Wang, Y., Wu, Y., & Wang, Z.-Y. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1226-y · Cited by 31 · see citing works
Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
Ghochikyan, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787847298 · Cited by 31 · see citing works
Mazzeo, S., Santangelo, R., Bernasconi, M. P., Cecchetti, G., Fiorino, A., Pinto, P., Passerini, G., Falautano, M., Comı, G., & Magnani, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160360 · Cited by 26 · see citing works
Meng, D., Hosseini, A. A., Simpson, R. J., Shaikh, Q., Tench, C. R., Dineen, R. A., & Auer, D. P. (2016) · Radiology · doi:10.1148/radiol.2016152685 · Cited by 22 · see citing works
Cerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-Review
Bibl, M., Mollenhauer, B., Esselmann, H., Schneider, M., Lewczuk, P., Welge, V., Gross, M., Falkai, P., Kornhuber, J., & Wiltfang, J. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000115975 · Cited by 26 · see citing works
Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
Bateman, R. J., & Klunk, W. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.009 · Cited by 26 · see citing works
Prosser, L., MacDougall, A. M., Sudre, C. H., Manning, E. N., Malone, I. B., Walsh, P., Goodkin, O., Pemberton, H., Barkhof, F., Biessels, G. J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201572 · Cited by 25 · see citing works
Spies, P. E., Claassen, J. A. H. R., Peer, P. G. M., Blankenstein, M. A., Teunissen, C. E., Scheltens, P., van der Flier, W. M., Rikkert, M. G. M. O., & Verbeek, M. M. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.010 · Cited by 23 · see citing works
Self-citationBenvenutto, A., Giusiano, B., Koric, L., Guériot, C., Didic, M., Felician, O., Guye, M., Guedj, E., & Ceccaldi, M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180292 · Cited by 23 · see citing works
Rosa‐Neto, P., Hsiung, G. R., Masellis, M., & participants, O. B. O. T. C. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt223 · Cited by 23 · see citing works
The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s Disease
Engelborghs, S., & Bastard, N. L. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/bf03262201 · Cited by 20 · see citing works
van de Sande, N., Ramakers, I. H. G. B., Visser, P. J., Verhey, F. R. J., Verbraak, F. D., Bouwman, F. H., Berendschot, T. T. J. M., Nuijts, R. M. M. A., Webers, C. A. B., & Gijs, M. (2023) · BMC Neurology · doi:10.1186/s12883-023-03335-y · Cited by 20 · see citing works
Neurochemical biomarkers in Alzheimer’s disease and related disorders
Bibl, M., Esselmann, H., & Wiltfang, J. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612455367 · Cited by 20 · see citing works
Poststroke dementia—what's in a name?
Tuladhar, A. M., & de Leeuw, F. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.229 · Cited by 19 · see citing works
Clinical indications for analysis of Alzheimer's disease CSF biomarkers
Engelborghs, S. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.024 · Cited by 20 · see citing works
Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40
Deming, Y. K., Black, K., Carrell, D., Cai, Y., Del‐Aguila, J. L., Fernández, M. V., Budde, J., Ma, S., Saef, B. A., Howells, B., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0742-9 · Cited by 18 · see citing works
Mazzeo, S., Polito, C., Padiglioni, S., Berti, V., Bagnoli, S., Lombardi, G., Piaceri, I., Carraro, M., Cristofaro, M. T. D., Passeri, A., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.004 · Cited by 18 · see citing works
Biomarkers for Alzheimer’s disease
Sonnen, J. A., Keene, C. D., Montine, K. S., Li, G., Peskind, E. R., Zhang, J., & Montine, T. J. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.8.1021 · Cited by 18 · see citing works
Diagnostic Utility of CSF Tau and Aβ42 in Dementia: A Meta‐Analysis
Agarwal, R., & Tripathi, C. B. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/503293 · Cited by 16 · see citing works
Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
Londoño, D., Arumaithurai, K., Constantopoulos, E., Basso, M. R., Reichard, R. R., Flanagan, E. P., & Keegan, B. M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac167 · Cited by 15 · see citing works
Tao, X., He, J., Zhang, Y., Yin, Y., Yang, C. G., Shang, Y., & Wu, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.018 · Cited by 13 · see citing works
Ou, Y., Shen, X., Hu, H., Hu, H., Wang, Z.-T., Xu, W., Dong, Q., Tan, L., & Yu, J. (2020) · Aging · doi:10.18632/aging.102921 · Cited by 13 · see citing works
Biomarkers in Alzheimer’s disease
Demarin, V., Zavoreo, I., Kes, V. B., & Šimundić, A.-M. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.139 · Cited by 14 · see citing works
Miller, A.-M., Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. J., Winblad, B. G., Waldemar, G., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170502 · Cited by 12 · see citing works
da Rosa, M. I., Perucchi, J. L., Medeiros, L. R., Fernandes, B. B., dos Reis, M. E. F., & Silva, B. R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132264 · Cited by 11 · see citing works
The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia
Engelborghs, S., & Bastard, N. L. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.08.003 · Cited by 11 · see citing works
van Doorn, L. J. C. V. W., Ghafoorian, M., van Leijsen, E. M. C., Claassen, J. A. H. R., Arighi, A., Bozzali, M., Cannas, J., Cavedo, E., Eusebi, P., Farotti, L., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200496 · Cited by 10 · see citing works
Self-citationBastard, N. L., Buggenhout, M. V., Leenheir, E. D., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2007) · The Journals of Gerontology Series A · doi:10.1093/gerona/62.8.923 · Cited by 10 · see citing works
Braissant, O., McLin, V. A., Sessa, D., & Pierzchała, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-21054-x · Cited by 9 · see citing works
Zou, Y., Yu, S., Ma, X., Ma, C., Mao, C., Mu, D., Li, L., Gao, J., & Qiu, L. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.11.013 · Cited by 9 · see citing works
CSF tau and amyloid β42 levels in Alzheimer’s disease—A meta-analysis
Agarwal, R., Chhillar, N., Mishra, V. N., & Tripathi, C. B. (2012) · Advances in Alzheimer s Disease · doi:10.4236/aad.2012.13005 · Cited by 9 · see citing works
Hosseini, A. A., Meng, D., Simpson, R., & Auer, D. P. (2017) · European Journal of Neurology · doi:10.1111/ene.13299 · Cited by 9 · see citing works
Biomarker pathway heterogeneity of amyloid‐positive individuals
Prosser, L., Sudre, C. H., Oxtoby, N. P., Young, A. L., Malone, I. B., Manning, E. N., Pemberton, H., Walsh, P., Barkhof, F., Biessels, G. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14287 · Cited by 7 · see citing works
Biomarker identification for diagnosis of Alzheimer's disease
Pelech, S. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2.5.577 · Cited by 6 · see citing works
Katsuse, K., Kakinuma, K., Kawakami, N., Ota, S., Ogawa, N., Kawamura, A., Iseki, C., Hamada, M., Toda, T., Matsuda, M., et al. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08100-2 · Cited by 5 · see citing works
Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Reis, H. J., Oliveira, A., Mukhamedyarov, M. A., Zefirov, A. L., Rizvanov, A. A., YALVAÇ, M. E., Teixeira, A. L., Janka, Z., Hussain, A., Vieira, L. B., et al. (2014) · Current Molecular Medicine · doi:10.2174/1566524014666140603114655 · Cited by 5 · see citing works
A Novel Computational Proxy for Characterizing Cognitive Reserve in Alzheimer’s Disease
Zhang, Y., Initiative, A. D. N., Hao, Y., Li, L., Xia, K., & Guorong Wu, A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201011 · Cited by 5 · see citing works
Biomarkører i spinalvæske ved demens
Skogseth, R. E., Fladby, T., Mulugeta, E., & Aarsland, D. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.10.0104 · Cited by 5 · see citing works
Genetic variants beyond amyloid and tau associated with cognitive decline
Kim, H., Lee, T., Choi, J. K., Jeong, Y., Weiner, M. W., Aisen, P., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010724 · Cited by 4 · see citing works
Alzheimer’s Disease Cerebrospinal Fluid (CSF) Biomarkers
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00005-5 · Cited by 4 · see citing works
Neurobiologische Frühdiagnostik der Alzheimer-Krankheit
Hampel, H. J., Teipel, S., & Bürger, K. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2317-x · Cited by 4 · see citing works
Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics
Bibl, M., & Wiltfang, J. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.153 · Cited by 4 · see citing works
Neue Perspektiven in der laborchemischen Diagnostik bei Demenzen
Bibl, M., & Wiltfang, J. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2498-y · Cited by 3 · see citing works
Slats, D., Spies, P. E., Sjögren, M. J. C., Verhey, F. R. J., Verbeek, M. M., & Rikkert, M. G. M. O. (2010) · Case Reports in Neurology · doi:10.1159/000286280 · Cited by 3 · see citing works
Self-citationThe Value of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Dementia
Bastard, N. L., & Engelborghs, S. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.11 · Cited by 1 · see citing works
Anti-inflammatory therapy and cerebrospinal fluid diagnosis in Alzheimer's disease.
de Jong, D. (2010) · Radboud Repository (Radboud University) · Cited by 1 · see citing works
POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA
de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2007) · The Journals of Gerontology Series A · doi:10.1093/gerona/62.8.924 · Cited by 1 · see citing works
Self-citationNeuropeptidomics : methods and applications.
Sköld, K. (2006) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1 · see citing works
Bétard, C., Boneschi, F., & Caramelli, P. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse237
Tau Protein, Ischemic Injury and Vascular Dementia
Mukaetova‐Ladinska, E. B., Li, M., & Kalaria, R. N. (2015) · Future Neurology · doi:10.2217/fnl.15.46
Amyloid beta: from pre-analytical factors to disease mechanisms
Toombs, J. (2019) · UCL Discovery (University College London)
Yin, C., Kindt, A. S. D., Harms, A. C., Hartman, R., Hankemeier, T., & de Lange, E. C. M. (2025) · Metabolomics · doi:10.1007/s11306-025-02350-z
Guo, Z., He, X., Ge, Y., Zhao, B. D., Huang, L.-Y., Chen, S., Fu, Y., Gao, P., Sheng, Z.-H., Huang, Y., et al. (2026) · European Journal of Neurology · doi:10.1111/ene.70558
- Authors
- de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M.
- Affiliations
- Pediatrics and Genetics (US)
- Radboud University Medical Center (NL)
- Venue
- The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07-01
- Volume
- 61
- Issue
- 7
- Pages
- 755-758
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- OpenAlex
- W2118174643
- Cited by
- 98
- References
- 18
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 7 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 6 · 2015: 7 · 2014: 10 · 2013: 3 · 2012: 7
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journals of Gerontology Series A (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- American Health Assistance Foundation
- Radboud Universiteit
- Hersenstichting
- Alzheimer Nederland
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, vascular dementia, cerebrospinal fluid biomarkers, amyloid-beta 42, phosphorylated tau, total tau, differential diagnosis, dementia
- MeSH terms
- Aged, Alzheimer Disease, Analysis of Variance, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Phosphorylation, ROC Curve, Sensitivity and Specificity, Dementia, Vascular, Biomarkers, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
